A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease

Trial Profile

A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Adrabetadex (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Biomarker; Pharmacokinetics
  • Sponsors CTD Holdings
  • Most Recent Events

    • 30 Apr 2018 According to a CTD Holdings media release, FDA has authorized application for extension study of this trial.
    • 29 Mar 2018 According to a CTD Holdings media release, initial review of safety data for this study has been completed.
    • 21 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top